OvaScience

NASDAQ

- -

- -

- -

- -

- -

- -

OvaScience, Inc., a fertility company, discovers, develops, and commercializes new fertility treatment options for women worldwide. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It engages in developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) consisting of AUGMENT to enhance the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment is used to replenish a woman's egg reserve by transferring the EggPCs from woman's own ovaries; OvaTure to produce mature fertilizable eggs from a woman’s own EggPC cells without the need for hormone injections; and OvaXon for the prevention of genetic disease and animal health. The company was formerly known as Ovastem, Inc. and changed its name to OvaScience, Inc. in May 2011. OvaScience, Inc. was founded in 2011 and is headquartered in Waltham, Massachusetts.